[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX370377B - Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado. - Google Patents

Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado.

Info

Publication number
MX370377B
MX370377B MX2015015043A MX2015015043A MX370377B MX 370377 B MX370377 B MX 370377B MX 2015015043 A MX2015015043 A MX 2015015043A MX 2015015043 A MX2015015043 A MX 2015015043A MX 370377 B MX370377 B MX 370377B
Authority
MX
Mexico
Prior art keywords
antibodies
interferon alpha
attenuated interferon
fusions
well
Prior art date
Application number
MX2015015043A
Other languages
English (en)
Other versions
MX2015015043A (es
Inventor
Clarke Adam
Gerard Doyle Anthony
Pollard Matthew
Behrens Collette
Yamagishi Tetsuo
S Jr Wilson David
L Pogue Sarah
Taura Tetsuya
Original Assignee
Teva Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Australia Pty Ltd filed Critical Teva Pharmaceuticals Australia Pty Ltd
Publication of MX2015015043A publication Critical patent/MX2015015043A/es
Publication of MX370377B publication Critical patent/MX370377B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen específicamente a CD38, así como también constructos que comprenden dichos anticuerpos fusionados con proteínas de interferón alfa-2b atenuado. Los constructos de fusión anti-CD38-INF alfa-2b atenuado pueden usarse para inhibir la proliferación en células cancerosas que expresan tanto CD38 como al receptor del IFN-alfa2b, así como también para inducir apoptosis en tales células. La inhibición de la proliferación y la inducción de la apoptosis en células cancerosas pueden servir como base para el tratamiento del cáncer subyacente.
MX2015015043A 2013-04-29 2013-04-29 Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado. MX370377B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/038659 WO2014178820A1 (en) 2013-04-29 2013-04-29 Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b

Publications (2)

Publication Number Publication Date
MX2015015043A MX2015015043A (es) 2016-08-11
MX370377B true MX370377B (es) 2019-12-11

Family

ID=48325957

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015043A MX370377B (es) 2013-04-29 2013-04-29 Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado.

Country Status (22)

Country Link
US (1) US9963515B2 (es)
EP (2) EP2992013B1 (es)
JP (1) JP6286532B2 (es)
KR (1) KR102094022B1 (es)
CN (2) CN110526971B (es)
AU (2) AU2013388126B2 (es)
BR (1) BR112015027313A2 (es)
CA (1) CA2909952C (es)
DK (1) DK3677591T5 (es)
EA (1) EA033115B1 (es)
ES (2) ES2774976T3 (es)
FI (1) FI3677591T3 (es)
IL (1) IL242296B (es)
MX (1) MX370377B (es)
NZ (1) NZ713641A (es)
PH (1) PH12015502439B1 (es)
PL (2) PL3677591T3 (es)
PT (2) PT3677591T (es)
SG (1) SG11201508923VA (es)
UA (1) UA113129C2 (es)
WO (1) WO2014178820A1 (es)
ZA (1) ZA201507789B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
HUE049945T2 (hu) 2012-03-03 2020-11-30 Immungene Inc Módosított antitest-interferon mutáns fúziós molekulák
HRP20171964T1 (hr) 2012-09-25 2018-02-23 Morphosys Ag Kombinacije i njihova upotreba
CN110526971B (zh) 2013-04-29 2023-06-30 泰华制药澳大利亚公司 抗-CD38抗体和与致弱干扰素α-2B的融合体
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (uk) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
EP3212216A4 (en) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants
TWI721959B (zh) 2014-12-04 2021-03-21 美商健生生物科技公司 治療急性骨髓性白血病之抗ｃｄ３８抗體
NZ775886A (en) 2015-05-20 2025-03-28 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
PE20181323A1 (es) 2015-06-22 2018-08-14 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
DK3313441T5 (da) 2015-06-24 2024-10-07 Janssen Biotech Inc Immunmodulering og behandling af faste tumorer med antistoffer, der specifikt binder cd38
US20180155411A1 (en) * 2015-07-08 2018-06-07 The Board Of Trustees Of The Leland Stanford Junior University Heterotypic antibodies specific for human rotavirus
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MY202415A (en) 2015-11-03 2024-04-27 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
AU2017226960B2 (en) 2016-03-04 2024-03-21 Morphosys Ag Clinical assessment of M-protein response in multiple myeloma
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
CA3030926A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy
WO2018015498A1 (en) 2016-07-20 2018-01-25 Hybrigenics Sa Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
KR102359192B1 (ko) * 2016-07-25 2022-02-04 세파론, 인코포레이티드 친화성 크로마토그래피 세정 완충액
AU2018288463A1 (en) * 2017-06-20 2020-01-30 Vivasor, Inc. CD38 antibody drug conjugate
JP2020525445A (ja) 2017-06-21 2020-08-27 セファロン・インコーポレイテッドＣｅｐｈａｌｏｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ カチオン交換クロマトグラフィーの洗浄緩衝液
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3703749A1 (en) 2017-10-31 2020-09-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
MX2021004465A (es) 2018-10-17 2021-08-24 Janssen Biotech Inc Método para proporcionar la administración subcutánea de anticuerpos anti-cd38.
IL283886B2 (en) 2018-12-14 2025-05-01 Morphosys Ag Antibody formulations
EP3914358A1 (en) * 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
AU2020226754A1 (en) 2019-02-20 2021-09-16 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
IL294655A (en) 2020-01-13 2022-09-01 Denali Therapeutics Inc Anti-trem2 antibodies and methods of use thereof
US12312400B2 (en) 2020-02-16 2025-05-27 Aulos Bioscience, Inc. Engineered anti-il-2 antibodies
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
US20250134962A1 (en) * 2021-08-12 2025-05-01 Shanghai Ttm-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
KR20240099411A (ko) 2021-11-03 2024-06-28 얀센 바이오테크 인코포레이티드 항-cd38 항체를 사용한 치료에서 코르티코스테로이드 감소
EP4472740A1 (en) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
CN119584982A (zh) * 2022-05-18 2025-03-07 武田药品工业株式会社 抗cd38融合蛋白制剂
TW202423968A (zh) * 2022-09-29 2024-06-16 日商武田藥品工業股份有限公司 Ｃｄ３８結合融合蛋白組合療法

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5558864A (en) 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
SK283889B6 (sk) 1994-03-17 2004-04-06 Merck Patent Gmbh Jednoreťazcové fragmenty protilátok a protilátky proti receptoru epidermálneho rastového faktoru, spôsob ich prípravy a farmaceutický prostriedok, ktorý ich obsahuje
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
HUP9901562A3 (en) 1996-05-04 2000-06-28 Astrazeneca Ab Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
NZ502375A (en) 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ATE327254T1 (de) 1998-10-16 2006-06-15 Biogen Idec Inc Interferon-beta fusionsproteine und deren verwendungen
NZ512185A (en) 1998-12-09 2004-02-27 Dow Chemical Co A method for manufacturing glycoproteins having human- type glycosylation in plant cells
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7355015B1 (en) 1999-03-12 2008-04-08 Georgetown University School Of Medicine Matriptase, a serine protease and its applications
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
AU2001265418B2 (en) * 2000-06-22 2006-03-30 Biogen Idec Inc. Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
PE20020801A1 (es) 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US7252994B2 (en) 2001-07-03 2007-08-07 Genentech, Inc. Human DR4 antibodies and uses thereof
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR100668538B1 (ko) 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JP2007524351A (ja) 2003-02-18 2007-08-30 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された特性を有するインターフェロンアルファムテインの融合タンパク質
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
DE10343708A1 (de) 2003-09-18 2005-05-12 Nexpress Solutions Llc Verfahren für das Befestigen von Toner an einem Bedruckstoff und Mikrowelleneinrichtung
EP1844815B1 (en) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
DK1720907T3 (en) * 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies as well as applications therefor
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7829673B2 (en) * 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
AR053489A1 (es) 2005-05-24 2007-05-09 Morphosys Ag Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
AU2006250068A1 (en) 2005-05-26 2006-11-30 Schering Corporation Interferon-IGG fusion
ES2436761T3 (es) 2005-06-29 2014-01-07 Yeda Research And Development Co., Ltd. Mutantes de interferón alfa 2 (IFN alfa 2) recombinante
KR20130023356A (ko) 2005-07-18 2013-03-07 메다렉스, 인코포레이티드 인간 항-ｂ7ｒｐ1 중화 항체
AU2006294663B2 (en) 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
KR101472250B1 (ko) 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
JP2009513147A (ja) 2005-10-31 2009-04-02 アメリカ合衆国 ヒト糖タンパクｎｍｂをターゲットにする抗体および免疫毒素
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
TW200902554A (en) 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
EP2152751A1 (en) 2007-05-31 2010-02-17 Genmab A/S Fusion or linked proteins with extended half life
US9364557B2 (en) 2007-08-01 2016-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fold-back diabody diphtheria toxin immunotoxin and methods of use
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
EP3150218B1 (en) 2007-09-21 2021-09-08 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
US8470320B2 (en) 2009-03-16 2013-06-25 Cephalon Australia Pty. Ltd. Humanised antibodies with anti-tumour activity
EP3613774A1 (en) * 2010-06-09 2020-02-26 Genmab A/S Antibodies against human cd38
MX350540B (es) 2010-09-27 2017-09-08 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl.
KR101941514B1 (ko) 2010-12-22 2019-01-23 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 개선된 반감기를 가지는 변형된 항체
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CA2861927C (en) 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
HUE049945T2 (hu) 2012-03-03 2020-11-30 Immungene Inc Módosított antitest-interferon mutáns fúziós molekulák
WO2014028502A1 (en) 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
CN110526971B (zh) 2013-04-29 2023-06-30 泰华制药澳大利亚公司 抗-CD38抗体和与致弱干扰素α-2B的融合体
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3212216A4 (en) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants

Also Published As

Publication number Publication date
AU2013388126A1 (en) 2015-11-12
KR102094022B1 (ko) 2020-03-30
US9963515B2 (en) 2018-05-08
AU2013388126B2 (en) 2019-03-07
PL3677591T3 (pl) 2023-06-26
JP2016522816A (ja) 2016-08-04
ZA201507789B (en) 2017-01-25
CN110526971A (zh) 2019-12-03
KR20160002864A (ko) 2016-01-08
US20160068612A1 (en) 2016-03-10
CN110526971B (zh) 2023-06-30
EA201592076A1 (ru) 2016-07-29
AU2019204016A1 (en) 2019-06-27
SG11201508923VA (en) 2015-11-27
FI3677591T3 (fi) 2023-04-03
ES2938708T3 (es) 2023-04-14
CA2909952C (en) 2021-10-12
PH12015502439B1 (en) 2019-01-11
MX2015015043A (es) 2016-08-11
PT2992013T (pt) 2020-03-05
EA033115B1 (ru) 2019-08-30
EP3677591A1 (en) 2020-07-08
EP2992013B1 (en) 2019-12-04
CN105473615B (zh) 2019-05-07
AU2019204016B2 (en) 2021-03-25
ES2774976T3 (es) 2020-07-23
CA2909952A1 (en) 2014-11-06
DK3677591T5 (da) 2024-08-26
JP6286532B2 (ja) 2018-02-28
EP2992013A1 (en) 2016-03-09
NZ713641A (en) 2019-08-30
CN105473615A (zh) 2016-04-06
BR112015027313A2 (pt) 2017-09-26
DK3677591T3 (da) 2023-03-20
PH12015502439A1 (en) 2016-03-28
IL242296B (en) 2020-06-30
WO2014178820A1 (en) 2014-11-06
PL2992013T3 (pl) 2020-09-07
HK1216650A1 (en) 2016-11-25
UA113129C2 (xx) 2016-12-12
EP3677591B1 (en) 2022-12-28
PT3677591T (pt) 2023-02-17

Similar Documents

Publication Publication Date Title
PH12015502439A1 (en) Anti-cd38 antibodies and fusions to attenuated inferferon alpha-2b
MX2020012573A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
NZ711445A (en) Fusion immunomodulatory proteins and methods for making same
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
TN2015000396A1 (en) Antibody drug conjugates
EP3964527A3 (en) Combination therapy for cancer
PH12015502087A1 (en) Newcastle disease viruses and uses thereof
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
PH12016500753A1 (en) Antibodies specific to fcrn
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
NZ607472A (en) Treatment for neoplastic diseases
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
EA201991027A1 (ru) АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
NZ742073A (en) Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
MX2019014848A (es) Anticuerpos anti-cd38 y fusiones con interferon alfa-2b atenuado.
PE20160028A1 (es) Anticuerpos anti-cd38 y fusiones con interferon alfa-2b atenuado
MX2023004302A (es) Anticuerpos anti-cd38 y fusiones con interferon alfa-2b atenuado.
MY195395A (en) Fusion Immunomodulatory Proteins and Methods for Making Same

Legal Events

Date Code Title Description
FG Grant or registration